Neutralization Testing–based Immunogenicity Analysis of Recent Prevalent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Sublineages-Reference-Cited by-同舟云学术

Neutralization Testing–based Immunogenicity Analysis of Recent Prevalent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Sublineages

Published:2023-12-13 Issue:3 Volume:44 Page:289-293
ISSN:2234-3806
Container-title:Annals of Laboratory Medicine
language:en
Short-container-title:Ann Lab Med

Author:

Lee Eun Ju¹²^ORCID,Lee Hyeokjin¹^ORCID,O Sang Won¹^ORCID,Rhee Jee Eun¹^ORCID,Kim Jeong-Min¹^ORCID,Kim Dong Ju¹^ORCID,Kim Il-Hwan¹^ORCID,No Jin Sun¹^ORCID,Park Ae Kyung¹^ORCID,Kim Jeong-Ah¹^ORCID,Lee Chae Young¹^ORCID,Choi Young-Ki²^ORCID,Kim Eun-Jin¹^ORCID

Affiliation:

1. Division of Emerging Infectious Diseases, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency (KDCA), Cheongju, Korea

2. College of Medicine and Medical Research Institute of Chungbuk National University, Cheongju, Korea

Funder

Korea Disease Control and Prevention Agency

Publisher

Annals of Laboratory Medicine

Subject

Biochemistry (medical),Clinical Biochemistry,General Medicine

Link

https://pdf.medrang.co.kr/ALM/2024/044/alm-44-3-289.pdf

Reference19 articles.

1. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (Updated on May 2023).

2. KDCA press release. https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=722664&cg_code=&act=view&nPage=2 (Updated on May 2023).

3. KDCA press release. https://www.kdca.go.kr/board/board.es?mid=a20501020000&bid=0015&list_no=723107&cg_code=C01&act=view&nPage=1 (Updated on July 26, 2023).

4. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants

5. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant